First precision T-cell engager for solid tumours enters the clinic
Clasp Therapeutics has announced the dosing of the initial patient in the GUARDIAN-101 Phase I trial of CLSP-1025, the first tumour-specific TCE to enter clinical development.
The company also presented non-clinical data for CLSP-1025 at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
Clasp’s approach centres on developing precision T-cell engagers (TCEs) with absolute tumour specificity by targeting oncogenic driver mutations presented by human leukocyte antigen (HLA) on cancer cells.
CLSP-1025 exclusively targets cancer cells expressing the p53 R175H mutation, a mutation associated with a wide range of solid tumours, including colorectal, pancreatic, lung, gastric, oesophageal, gynaecological, and prostate cancers.
Unlike first-generation TCEs that target proteins present on both tumour and normal cells, Clasp says its TCEs target tumour-specific peptides derived from cancer driver mutations, ensuring absolute specificity and minimising risk of toxicity to healthy tissues.
Truncal mutations like p53 R175H occur early in tumorigenesis and are present in every tumour cell, making them ideal targets for immune system attack. Moreover, these pHLAre molecules (precise HLA redirecting engagers) are designed to mimic the natural T cell receptor interface between a cancer cell and T cell, maximising anti-cancer activity.
“At Clasp, we’re pioneering a new era of precision immuno-oncology – one that goes straight to the source by targeting the mutations that drive cancer formation and progression,” said Vipin Suri, Chief Scientific Officer of Clasp Therapeutics. “The nonclinical data we presented reinforce the promise of our approach and the potential of CLSP-1025 in the GUARDIAN-101 Phase I trial.”
The preclinical data show that CLSP-1025 induced robust, targeted T cell activation, resulting in significant regression of KMS-26 tumour xenografts in vivo.
It did not cause target independent T cell activation or cytokine release in peripheral blood mononuclear cells (PBMCs) or show any activity towards normal healthy tissue.
DIANA SPENCER, Senior Digital Content Editor, DDW
